Jefferies Upgrades Rigel Pharmaceuticals to Buy, Raises Price Target to $42
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and raises the price target from $23 to $42.
Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and raises the price target from $23 to $42.